Wells Fargo analyst Stephen Baxter lowered the firm’s price target on Humana (HUM) to $290 from $347 and keeps an Overweight rating on the shares. The firm is also lowering estimates on refined star rating headwind given clarity on VBC / Group MA dynamics.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Trump says ‘enrichment’ of health insurers ‘must stop’
- Humana price target lowered to $310 from $345 at Mizuho
- Humana price target lowered to $231 from $250 at Deutsche Bank
- Humana’s Hold Rating: Balancing Positive Earnings with Strategic Challenges
- Humana’s Strategic Focus on Medicare Advantage and Future Margin Expansion Amidst Uncertain Guidance